Publications by authors named "Lisa Musick"

Claim this Profile
P
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.
Yuqin Song, Qingyuan Zhang, Qingqing Cai, Yongping Song, Liling Zhang, Lisa Musick

J Cancer Res Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated Lugano Metabolic Response Assessment in F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on F-Fluorodeoxyglucose-Positron Emission Tomography.
Skander Jemaa, Souhila Ounadjela, Xiaoyong Wang, Tarec C El-Galaly, Lale Kostakoglu, Lisa Musick

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Sam Yuen, Tycel J Phillips, Rajat Bannerji, Paula Marlton, Giuseppe Gritti, Lisa Musick

Am J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, Mark Hertzberg, Sarit Assouline, Lisa Musick

Haematologica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Pau Abrisqueta, Eva González-Barca, Carlos Panizo, José María Arguiñano Pérez, Fiona Miall, Lisa Musick

Lancet Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Lisa Musick

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Alex F Herrera, Samuel Tracy, Brandon Croft, Stephen Opat, Jill Ray, Lisa Musick

Blood Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Laurie H Sehn, Mark Hertzberg, Stephen Opat, Alex F Herrera, Sarit Assouline, Lisa Musick

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Catherine Diefenbach, Brad S Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Lisa Musick

Lancet Haematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population.
Emily R Levy, Lisa Musick, Matthew S Zinter, Tess Lang, Mort J Cowan

Pediatr Infect Dis J· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Janel R Long-Boyle, Rada Savic, Shirley Yan, Imke Bartelink, Lisa Musick

Ther Drug Monit· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Jason Law, Morton J Cowan, Christopher C Dvorak, Lisa Musick, Janel R Long-Boyle

Biol Blood Marrow Transplant· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis